Evaluating clinical research: All that glitters is not gold

Evaluating Clinical Research: All that Glitters is not Gold

Volumn , Issue , 2007, Pages 1-158

  Furberg, Bengt D ^a   Furberg, Curt D ^b  

^a Wake Forest University School of Medicine ^*

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892358004     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-72899-5     Document Type: Book

References (161)

1. Friedman LM, Furberg CD, DeMets DL. Fundamentals of Clinical Trials. New York, Springer- Verlag, 1998 (3rd ed.).
2. DeMets DL, Furberg CD, Friedman LM, eds. Data Monitoring in Clinical Trials. A Case Studies Approach. New York, Springer, 2006.
3. Friedman LM, Furberg CD, DeMets DL. Fundamentals of Clinical Trials. New York, Springer- Verlag, 1998 (3rd ed.).
4. Piantadosi S. Clinical Trials: A Methodologic Perspective. New York, John Wiley & Sons, Inc., 1997.
5. Pocock S. Clinical Trials: A Practical Approach. West Sussex, England, John Wiley & Sons, Ltd., 1983.
6. Simpson J, Speake J. The Concise Oxford Dictionary of Proverbs. Oxford, Oxford University Press, 1998.
7. Berra Y. The Yogi Book. "I Really Didn't Say Everything I Said." New York, Workman Publishing, 1998.
8. National Association of Attorneys General. Settlement: Fifty Attorney Generals announce settlement with Pfizer over improper off-label drug marketing. http://www.naag.org/issues/20040513-settlement-pfizer.php.
9. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med 2006;166:1021-1026.
10. Friedman LM, Furberg CD, DeMets DL. Fundamentals of Clinical Trials. New York, Springer- Verlag, 1998 (3rd ed.).
11. Guidance for Industry. E6 Good Clinical Practice: Consolidated Guidance. ICH, April 1996. www.fda.gov/cder/guidance/959fnl.pdf.
12. Hypertension Detection and Follow-up Program Cooperative Group: Five-year findings of the Hypertension Detection and Follow-up Program. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 1979;242:2562-71.
13. Karlowski TR, Chalmers TC, Frenkel LD, et al. Ascorbic acid for common cold. A prophylactic and therapeutic trial. JAMA 1975;231:1038-42.
14. Parsons HM. What happened at Hawthorne? Science 1974;183:922-32.
15. Vandenbroucke JP. Benefits and harms of drug treatments. Br Med J 2004;329:2-3.
16. Bailey DG, Malcolm J, Arnold O, et al. Grapefruit juice-drug interactions. 1998. Br J Clin Pharmacol 2001;52:216-7.
17. Cleland JG, Cohen-Solal A, Aguilar JC, et al. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): An international survey. Lancet 2002;360:1631-9.
18. Connolly H, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluraminephentermine.N Engl J Med 1997;337:581-8.
19. Källén BA, Otterblad-Olausson P, Danielsson B. Is erythromycin therapy teratogenic in humans? Reprod Toxicol 2005; 20:209-14.
20. Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000;343:1826-32.
21. Laughren T. Premarketing studies in the drug approval process: understanding their limitations regarding the assessment of drug safety. Clin Ther 1998;20 Suppl C:C12-9.
22. Mortimer Ö (1999). Personal communication.
23. Venning GR. Identification of adverse reactions to new drugs II: how were 18 important adverse reactions discovered and with what delays? Br Med J 1983;286:289-92.
24. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. JAMA 2000;284:3043-5.
25. Alderson P, Roberts I. Corticosteroids in acute traumatic brain injury: Systematic review of randomised controlled trials. Br Med J 1997;314:1855-9.
26. Cochrane Injuries Group Albumin Reviewers. Human albumin administration in critically ill patients: Systematic review of randomised controlled trials. Br Med J 1998;317:235-40.
27. CRASH Trial Collaborators. Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC Crash trial): Randomized placebocontrolled trial. Lancet 2004;364:1321-8.
28. Jüni P, Nartey L, Reichenback S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: Cumulative meta-Analysis. Lancet 2004:364:2021-9.
29. LeLorier J, Gregoire G, Benhaddad A, et al. Discrepancies between meta-Analyses and subsequent large randomized, controlled trials. N Engl J Med 1997;337:536-42.
30. Rothstein H, Sutton A, Borenstein M (eds). Publication Bias in Meta-Analysis: Prevention, Assessment, and Adjustments. London, John Wiley & Sons, Ltd., 2005.
31. The SAFE Study Investigators: A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004;350:2247-56.
32. Sauerland S, Maegele M. A CRASH landing in severe head injury. Lancet 2004;364:1291-2.
33. Young D. ASHP News: Congress investigates FDA's handling of antidepressant safety information. November 1, 2004. http://www.ashp.org/news/ ShowArticle.cfm?id=8375.
34. Doll R, Hill AB. The mortality of doctors in relation to their smoking habits. A preliminary report. Br Med J 1954;4877:1451-5.
35. Doll R, Peto R, Boreham J, et al. Mortality in relation to smoking: 50 years' observations on male British doctors. Br Med J 2004;328:1519-27.
36. Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000;343:1826-32.
37. McBride WG. Thalidomide and congenital abnormalities. Lancet 1961;278:1358.
38. Venning GR. Identification of adverse reactions to new drugs II: how were 18 important adverse reactions discovered and with what delays? Br Med J 1983;286:289-92.
39. Hulley S, Grady D, Bush T, et al., Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.
40. Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet 2000;356:1627-31.
41. Petitti DB. Hormone replacement therapy and heart disease prevention. Experimentation trumps observation. JAMA 1998;280:650-2.
42. Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 2002;59:223-7.
43. Venning GR. Validity of anecdotal reports of suspected adverse drug reactions: The problem of false alarms. Br Med J 1982;284:249-52.
44. Wolozin B, Kellman W, Ruosseau P, et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3 methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000;57:1439-43.
45. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
46. Chan AW, Hróbjartsson A, Haahr MT, et al. Empirical evidence for selective reporting of outcomes in randomized trials. Comparison of protocols to published articles. JAMA 2004;291:2457-65.
47. Chan AW, Krleza-Jeric K, Schmid I, et al. Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. CMAJ 2004;171:735-40.
48. DeAngelis CD, Drazen JM, Frizelle FA, et al. Clinical trial registration: A statement from the International Committee of Medical Journal Editors. JAMA 2004;292:1363-4.
49. Goudie RB. The birthday fallacy and statistics of Icelandic diabetes. Lancet 1981;2:1173.
50. Haug C, Gøtzsche PC, Schroeder TV. Registries and registration of clinical trials. N Engl J Med 2005;353:2811-2.
51. Sears MR, Taylor DR, Print CG, et al. Regular inhaled ?-Agonist treatment in bronchial asthma. Lancet 1990;336:1391-6.
52. Sim I, An-Wen C, Gülmezoglu AM, et al. Clinical trial registration: Transparency is the watchword. Lancet 2006;367:1631-3.
53. Zarin DA, Tse T, Ide NC. Trial registration at ClinicalTrials.gov between May and October 2005. N Engl J Med 2005;353:2779-87.
54. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-6.
55. Peto R. Failure of randomization by "sealed" envelope. Lancet 1999;354;73.
56. Hulley S, Grady D, Bush T, et al., Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.
57. Karlowski TR, Chalmers TC, Frenkel LD, et al. Ascorbic acid for common cold. A prophylactic and therapeutic trial. JAMA 1975;231:1038-42.
58. DuBeau CE, Yalla SV, Resnick NM. Implications of the most bothersome prostatism symptomfor clinical care and outcomes research. J Amer Geriatr Soc 1995;43:985-9
59. Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986;314:1657-64.
60. Jachuck SJ, Brierley H, Jachuck S, et al. The effect of hypotensive drugs on the quality of life. J R Coll Gen Pract 1982;32:103-5.
61. DeMets DL, Califf RM. Lessons learned from recent cardiovascular clinical trials: Part I. Circulation 2002;106:746-751.
62. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecanide or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-8.
63. Fleming TR, DeMets DL. Surrogate end points in clinical trials: Are we being mislead? Ann Intern Med 1996;125:605-13.
64. Hulley S, Grady D, Bush T, et al., Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.
65. Riggs BL, Hodgson SF, O'Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990;322:802-9.
66. Temple RJ. A regulatory authority's opinion about surrogate endpoints. In Nimmo WS, Tucker GT, eds: Clinical Measurement in Drug Evaluation. New York, John Wiley & Sons, Inc., 1995.
67. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8.
68. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
69. Furberg CD, Levin AA, Gross PA, Shapiro RS, Strom BL. FDA and drug safety - A proposal for sweeping changes. Arch Intern Med 2006;166:1938-42.
70. Gunnell D, Ashby D. Antidepressants and suicide: what is the balance of benefit and harm. Br Med J 2004;329:34-8.
71. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: An evaluation of 7 medical areas. JAMA 2001;285:437-43.
72. Kelly WN. Can the frequency and risks of fatal adverse drug events be determined? Pharmacotherapy 2001;21:521-7.
73. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-Analysis of prospective studies. JAMA 1998;279:1200-5.
74. Pirmohamed M, James S, Green C, et al. Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18, 820 patients. Br Med J 2004;329:15-9.
75. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55.
76. Solomon S, McMurray JJV, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
77. Strom BL. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: A counterpoint. JAMA 2004;292:2643-6.
78. Wang PS, Bohn RL, Glynn RJ, et al. Hazardous benzodiazepine regimens in the elderly: Effects of half-life, dosage, and duration on risk of hip fracture. Am J Psychiatry 2001;158:892-8
79. Furberg CD, Hawkins CM, Lichstein E, for the Beta-Blocker Heart Attack Trial Study Group. Effect of propranolol in postinfarction patients with mechanical or electrical complications. Circulation 1984;69:761-5.
80. Kaariainen I, Sipponen P, Siurala M. What fraction of hospital ulcer patients is eligible for prospective drug trials? Scand J Gastroenterol 1991;186:73-6.
81. Psaty BM, Rhoads C, Furberg CD. Evidence-based medicine. Worship of form and treatment of high blood pressure. J Gen Intern Med 2000;15:755-6.
82. Rochon PA, Berger PB, Gordon M. The evolution of clinical trials: Inclusion and representation. CMAJ 1998;159:1373-4.
83. Anturane Reinfarction Trial Research Group: Sulfinpyrazone in the prevention of sudden death after myocardial infarction. N Engl J Med 1980;302:250-6.
84. Coronary Drug Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. N Engl J Med 1980;303:1038-41.
85. Granger BB, Swedberg K, Ekman I, et al. for the CHARM investigators. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: Double-blind, randomised, controlled clinical trial. Lancet 2005;366:2005-11.
86. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-Analysis of the association between adherence to drug therapy and mortality. Br Med J, 2006; 333:15; doi:10.1136/bmj.38875.675486.55.
87. Temple R, Pledger GW. The FDA's critique of the Anturane Reinfarction Trial. N Engl J Med 1980;303:1488-92.
88. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: Is it a wise choice? Lancet 2004;364:1684-9.
89. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002;359:995-1003.
90. Dahlöf B, Sever PS, Poulter NR, et al. for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomized controlled trial. Lancet 2005;366:895-906.
91. Danish Omeprazole Study Group. Omeprazole and cimetidine in the treatment of ulcers of the body of the stomach: A double blind comparative trial. Br Med J 1989;298:645-7.
92. Dormandy JA, Charbonnel B, Eckland DJA, et al. on behalf of the PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): A randomized controlled trial. Lancet 2005;366:1279-89.
93. Freemantle N, Cleland J, Young P, Mason J, Harrison J. ?-blockade after myocardial infarction: Systematic review and meta regression analysis. Br Med J 1999;318:1730-7.
94. Francis CW, Berkowitz SD, Comp PC, et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003;349:1703-12.
95. Heres S, Davis J, Maino K, et al. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: An exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 2006;163:185-94.
96. Johansen HK, Gøtzsche PC. Problems in the design and reporting of trials of antifungal agents encountered during meta-Analysis. JAMA 1999;282:1752-9.
97. Jørgensen KJ, Johansen HK, Gøtzsche PC. Flaws in design, analysis and interpretation of Pfizer's antifungal trials of voriconazole and uncritical subsequent quotations. Trials 2006;7:3.
98. Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: A randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000;14:1249-58.
99. Lindholm LH, Carlberg B, Samuelsson O. Should ?-blockers remain first choice in the treatment of primary hypertension? A meta-Analysis. Lancet 2005;366:1545-53.
100. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): Randomised controlled trial. Lancet 2003;362:7-13.
101. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents. A network meta-Analysis. JAMA 2003;289:2534-44.
102. Psaty BM, Weiss N, Furberg CD. Recent trials in hypertension. Compelling science orcommercial speech? JAMA 2006;295:1704-6.
103. Rochon PA, Gurwitz JH, Simms RW, et al. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Arch Intern Med 1994;154:157-63.
104. Watson P, Stjernchantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-Angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology 1996;103:126-37.
105. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. JAMA 2000;284:3043-5.
106. Briel M, Schwartz GC, Thompson PL et al. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes. A meta-Analysis of randomized controlled trials. JAMA 2006;295:2046-56.
107. Dahlöf B, Deveveux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002;359:995-1003.
108. Dormandy JA, Charbonnel B, Eckland DJA, et al. on behalf of the PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): A randomized controlled trial. Lancet 2005;366:1279-89.
109. Freemantle N, Calvert M, Wood J, et al. Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA 2003;289:2554-9.
110. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study: A randomized controlled trial. JAMA 2001;285:1711-8.
111. Collins R, Peto R, Armitage J. The MRC/BHF Heart Protection Study: Preliminary results. Int J Clin Pract 2002;56:53-6.
112. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients with lipid-lowering drugs. JAMA 2004;292:2585-90.
113. PROGRESS Collaborative Group: Randomised trial of perindopril-based blood pressurelowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41.
114. Psaty BM, Furberg CD, Ray WA, et al. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. JAMA 2004;292:2622-31.
115. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: A randomized controlled trial. JAMA 2001;285:1585-91.
116. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
117. Angell M, Utiger RD, Wood AJ. Disclosure of authors' conflicts of interest: A follow-up. N Engl J Med 2000;342:586-7.
118. Barnes DE, Bero LA. Why review articles on the health effects of passive smoking reach different conclusions. JAMA 1998;279:1566-70.
119. Cain DM, Loewenstein G, Moore DA. The dirt on coming clean: Perverse effects of disclosing conflicts of interest. J Legal Studies 2005:34:1-25.
120. Djulbegovic B, Lacevic M, Cantor A, et al. The uncertainty principle and industry-sponsored research. Lancet 2000;356:635-8.
121. Chaudhry S, Schroter S, Smith R, Morris J. Does declaration of competing interests affect readers' perceptions? A randomised trial. Br Med J 2002;325:1391-2.
122. Heres S, Davis J, Maino K, et al. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: An exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 2006;163:185-94.
123. Kjaergard LL, Als-Nielsen B. Association between competing interests and authors' conclusions: Epidemiological study of randomised clinical trials published in the BMJ. Available online at http://bmj.com/cgi/content/full/325/ 7358/249#BIBL .
124. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: Systematic review. Br Med J 2003;326:1167-70.
125. Ridker PM, Torres J. Reported outcomes in major cardiovascular clinical trials funded by forprofit and not-for-profit organizations: 2000-2005. JAMA 2006;295:2270-4.
126. Stelfox HT, Chua G, O'Rourke K, Detsky AS. Conflict of interest in the debate over calciumchannel antagonists. N Engl J Med 1998;338:101-6.
127. Chan AW, Altman DG. Epidemiology and reporting of randomised trials published in PubMed journals. Lancet 2005;365:1159-62.
128. Chan AW, Altman DG. Identifying outcome reporting bias in randomised trials on PubMed: Review of publications and survey of authors. Br Med J 2005;330:753-9.
129. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence based medicine-selective reporting from studies sponsored by pharmaceutical industry: Review of studies in new drug applications. Br Med J 2003;326:1171-3.
130. Mills EJ, Wu P, Gagnier J, Devereaux PJ. The quality of randomized trial reporting in leading medical journals since the revised CONSORT statement. Contemp Clin Trials 2005;26:480-7.
131. O'Shea JC, Califf RM. International differences in cardiovascular clinical trials. Am Heart J 2001;141:866-74.
132. Relman AS. Are we a filter or a sponge? N Engl J Med 1978;299:197.
133. Rothstein H, Sutton A, Borenstein M (eds). Publication Bias in Meta-Analysis: Prevention, Assessment, and Adjustments. London, John Wiley & Sons, Ltd., 2005.
134. Vickers A, Goyal N, Harland R, Rees R. Do certain countries produce only positive results? A systematic review of controlled trials. Controlled Clin Trials 1998;19:159-66.
135. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither, among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;ii:349-60.
136. Oakes D, Moss AJ, Fleiss JL, et al. Use of compliance measures in an analysis of the effect of diltiazem on mortality and reinfarction after myocardial infarction. J Am Stat Assoc 1993;88:44-9.
137. Peto R. Statistical aspects of cancer trials, In Halnan KE, ed: Treatment of Cancer. London, Chapman & Hall, 1982.
138. Furberg CD, Herrington DM, Psaty BM. Are drugs within a class interchangeable? Lancet 1999;354:1202-4.
139. Furberg CD, Pitt B. Are all angiotensin-converting enzyme inhibitors interchangeable? J Am Coll Cardiol 2001;37:1456-60.
140. Luzier AB, Forrest A, Adelman M, et al. Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure. Am J Cardiol 1998;82:465-9.
141. Pitt B, O'Neill B, Feldman R, et al. The QUinapril Ischemic Event Trial (QUIET): Evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 2001;87:1058-63.
142. PROGRESS Collaborative Group: Randomised trial of perindopril-based blood pressurelowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41.
143. Bell CM, Urbach DR, Ray JG, et al. Bias in published cost effectiveness studies: Systematic review. Br Med J 2006;332:699-703.
144. Cranor CW, Bunting BA, Christensen DB. The Asheville Project: Long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc 2003;43:173-84.
145. Friedberg M, Saffran B, Stinson TJ, et al. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA 1999;282:1453-7.
146. Hill SR, Mitchell AS, Henry DA. Problems with the interpretation of pharmacoeconomic analyses. A review of submissions to the Australian pharmaceutical benefits scheme. JAMA 2000;283:2116-21.
147. Hillman AL, Eisenberg JM, Pauly MV, et al. Avoiding bias in the conduct and reporting of costeffectiveness research sponsored by pharmaceutical companies. N Engl J Med 1991:324:1362-5.
148. Kassirer JP, Angell M. The journal's policy on cost-effectiveness analyses. N Engl J Med 1994;331:669-70.
149. Paterson ML. Cost-benefit evaluation of a new technology for treatment of peptic ulcer disease. Manage Decis Econ 1983;4:50-62.
150. Djulbegovic B. Lifting the fog of uncertainty from the practice of medicine. Br Med J 2004;329:1419-20.
151. Guyatt GH, Sackett DL, Cook DJ. Users' Guides to the Medical Literature: II. How to use an article about therapy or prevention: A Are the results of the study valid? JAMA 1993;270:2598-601.
152. Guyatt GH, Rennie D. Users' Guides to the Medical Literature: Essentials of Evidence-Based Clinical Practice. Chicago, IL, AMA Press, 2002.
153. Collins R, Julian D. British Hearth Foundation surveys (1987 and 1989) of United Kingdom treatment policies for acute myocardial infarction. Br Heart J 1991;66:250-5.
154. Friedman L, Wenger NK, Knatterud GL. Impact of the Coronary Drug Project findings on clinical practice. Controlled Clin Trials 1983;4:513-22.
155. Furberg RD, Furberg CD. Evaluating professional performance in cardiovascular medicine. Evid Based Cardiovas Med 2006;10:75-8.
156. Grol R, Grimshaw J. From best evidence to best practice: Effective implementation of change in patients' care. Lancet 2003;362:1225-30.
157. Hyman DJ, Pavlik VN. Self-reported hypertension treatment practices among primary carephysicians. Blood pressure thresholds, drug choices, and the role of guidelines and evidencebased medicine. Arch Intern Med 2000;160:2281-6.
158. Lamas GA, Pfeffer MA, Hamm P, et al. Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? N Engl J Med 1992;327:241-7.
159. McGlynn EA, Asch SM, Adams J, et al. The quality of health care delivered to adults in the United States. N Engl J Med 2003;348:2635-45.
160. Reiffel JA, Cook JR. Physician attitudes toward the use of type IC antiarrhythmics after the Cardiac Arrhythmia Suppression Trial (CAST). Am J Cardiol 1990;66:1262-4.
161. Williams SC, Schmaltz SP, Morton DJ, et al. Quality of care in US hospitals as reflected by standardized measures, 2002-2004. N Engl J Med 2005;353:265-74.